微流控芯片

Search documents
美好医疗(301363):产能转移业绩短期承压 公司第二、第三增长点有望逐步兑现
Xin Lang Cai Jing· 2025-09-23 06:39
Core Insights - The company reported a revenue of 733 million yuan for H1 2025, representing a year-on-year increase of 3.73%, while the net profit attributable to the parent company was 114 million yuan, a decrease of 32.44% year-on-year [1] Business Analysis - The company experienced strong growth in emerging business sectors, with home respiratory device components generating 436 million yuan (down 2.76% year-on-year), cochlear implant components at 60 million yuan (down 7.53% year-on-year), other medical product components at 76 million yuan (up 54.41% year-on-year), and home and consumer electronics components at 107 million yuan (up 35.69% year-on-year). The company plans to increase investment in strategic emerging business areas to establish a solid foundation for long-term sustainable development [2] - The company is diversifying its business layout in multiple segments such as blood glucose management, cardiovascular, and in vitro diagnostics, aiming to create second and third growth curves. In the blood glucose management sector, breakthroughs have been made in disposable injection pens, continuous glucose monitoring (CGM) devices, and insulin patch pumps. A fully automated production project for insulin injection pens customized for international clients has achieved large-scale production, and the core R&D work for the self-designed "Beautiful Pen" has been completed, with client expansion progressing smoothly [2] - In the in vitro diagnostics field, the company has leveraged its strong technical foundation to achieve significant R&D results in microfluidic chips, detection consumables, reagent packaging materials, and precision components for instruments. Some products have been delivered for validation in small batches, and future business development will be driven by existing customer needs [3] Profit Forecast - The company forecasts revenues of 1.829 billion yuan, 2.294 billion yuan, and 2.741 billion yuan for 2025-2027, with year-on-year growth rates of 14.74%, 25.42%, and 19.47% respectively. The net profit attributable to the parent company is expected to be 402 million yuan, 488 million yuan, and 605 million yuan, with year-on-year growth rates of 10.56%, 21.44%, and 23.92%. The price-to-earnings (PE) ratios for 2025-2027 are projected to be 36.08, 29.71, and 23.98, with corresponding price-to-earnings growth (PEG) ratios of 3.42, 1.39, and 1.00 [4]
中国芯力量|藏粮于技的“芯”应用
Xin Hua She· 2025-09-12 09:42
微流控芯片被称为"芯片实验室",是在微米尺度空间上构建的流体操作平台,可以将传统实验室中的操 作集合在一起,基于微流体力学原理控制流体的速度、方向和混合程度,实现复杂的化学和生物反应。 中国科学院合肥物质科学研究院智能机械研究所研发的这款芯片,微电极采用3D环绕结构,可以提高 检测灵敏度,解决了传统微流控芯片难以检测土壤磷含量的难题,十几分钟内就可以对土壤中的营养元 素进行全面定量分析。 成本低、检测速度快,这款微流控芯片可以在田间地头随时检测,快速了解土壤肥力,制定合理施肥方 案,避免浪费。此外,基于定期检测,还可以助农追踪土壤养分变化趋势,为选择适宜土壤成分的农作 物品类提供解决方案。甚至还可以精细化检测,为田块级施肥奠定基础,从而提升农作物品质和产量, 减少资源浪费和土壤污染。 管护:身体康健"护理员" 悠悠万事,吃饭为大。从原始的刀耕火种到现代智慧农业,人类对粮食产量与安全的追求从未停歇。农 作物生产是集合"耕、种、管、收、储、运、销"的完整链条,以芯片为"神经中枢"的科技赋能全产业 链,不断推动传统农业向精准化、高效化转型,让"藏粮于技"从战略理念转化为实实在在的产能提升。 耕种:土壤营养"体检师" ...
2025年中国微流控行业相关政策、市场规模及趋势分析
Sou Hu Cai Jing· 2025-09-01 06:36
| | | 微流控行业相关政策 | | --- | --- | --- | | 时间 | 政策名称 | 王要内容 | | 2023年12月 | 《关于全国推进紧密型 | 统筹建立县域内医学检验、医学影像、心 | | | | 病理诊断、消毒供应等资源共享中心;将 | | | 县域医疗卫生共同体建 | | | | 设的指导意见》 | 延伸到乡村,推行县层检查、上级诊断、 | | | | 加强检查检验、疾病诊断质量监测评价。 | | 2023年3月 | | 要求扎实推进医用耗材集中带量采购,按 | | | 《关于做好2023年医药 | 策的原则开展新批次国家组织高值医用耗 | | | 集中采购和价格管理工 | 提高集采精细化管理水平,创新完善集采 | | | 作的通知》 | 力提高报量准确性,强化落实优先使用中 | | | | 加强中选产品供应保障。 | | 2022年5月 | | 发展微流控芯片、细胞制备目动化等先进 | | | 《"十四五"生物经济 | 动抗体药物、重组蛋白、多肽、细胞和基 | | | 发展规划 » | 品等生物药发展,鼓励推进慢性病、肿瘤 | | | | 行性疾病等重大疾病和学儿病的原创药物 ...
恒生医疗ETF(513060)交投活跃,近2周新增规模居可比基金首位,政策支持高端医疗器械快速发展
Sou Hu Cai Jing· 2025-07-10 03:49
Group 1: Market Performance - The Hang Seng Healthcare Index (HSHCI) decreased by 0.18% as of July 10, 2025, with mixed performance among constituent stocks [3] - Major gainers included Giant Bio (02367) up 4.24%, Yaoshi Bang (09885) up 4.13%, and Dongyangguang Changjiang Pharmaceutical (01558) up 3.48% [3] - The Hang Seng Healthcare ETF (513060) fell by 0.17%, with a latest price of 0.58 yuan, but saw a 2.48% increase over the past week [3] Group 2: Regulatory Developments - The National Medical Products Administration (NMPA) announced measures to optimize lifecycle regulation to support high-end medical device innovation, particularly benefiting the in vitro diagnostics (IVD) industry [4] - Policies include accelerated approvals and international registration facilitation, which will enhance the global competitiveness of IVD companies [4] - The document from NMPA is expected to directly benefit the IVD sector, with domestic biochemical diagnostics largely free from foreign constraints [4] Group 3: ETF Performance Metrics - The Hang Seng Healthcare ETF recorded a financing buy-in of 220 million yuan and a financing balance of 267 million yuan [5] - Over the past two years, the ETF's net value increased by 20.23%, with a maximum monthly return of 28.34% and an average monthly return of 6.82% [5] - As of July 4, 2025, the ETF's one-year Sharpe ratio was 2.07, indicating strong risk-adjusted returns [5] Group 4: Valuation and Tracking - The Hang Seng Healthcare ETF has a current price-to-earnings ratio (PE-TTM) of 27.84, which is below the historical average, indicating a low valuation compared to the past three years [6] - The ETF has the highest tracking accuracy among comparable funds, with a tracking error of 0.069% over the past year [5][6] - The ETF's management fee is 0.50%, and the custody fee is 0.15%, contributing to its overall cost structure [5]
甬江实验室苏瑞涛:微流控器件3D打印将逐渐取代软光刻
DT新材料· 2025-06-23 14:33
甬江实验室 特聘研究员 苏瑞涛 将出席 2025(第四届)高分子3D打印材料高峰论坛 (7月18-20 日 | 浙江 · 杭州),并分享 "功能材料与器件的 3D 打印" 。 高精度3D打印技术(如双光子聚合、电流体动力喷印和计算轴向光刻)可制造特征尺寸低至 100纳 米 的复杂结构。 近年来,关于 3D打印微流控器件 的研究和进展越来越来。许多研究人员采用了3D打印技术作为制 造微流控芯片的技术手段,3D打印技术为微流控芯片制备的标准化和批量生产提供了广阔的前景。 由于3D打印具有快速反馈和3D几何图形的自由成型的能力,这为微流控芯片的生产提供了很好的支 撑,并带来微流控芯片的类型和尺寸等方面的创新。除此之外,在3D打印机精密控制、新材料开发 和高分辨率打印等方面改进可以制作更小更复杂的3D打印微流控系统,从而带来微流控芯片制造方 法的变革。 微流控芯片制造技术从半导体微纳制造技术衍生而来。微流控芯片具有 功耗低、自动化程度高、分 析速度快、样本量小、批量制造、多通道分析一体化 等优点,该技术可以大大提高实验效率,减少 材料消耗,节省时间和金钱成本。 近年,甬江实验室的 苏瑞涛研究员 在其综述中详细地介绍了 ...
一流研究院所开门迎民企
Zheng Zhou Ri Bao· 2025-06-20 00:46
Group 1 - The event "Science and Innovation Zhengzhou · Co-creating the Future" aims to build a collaborative innovation platform between government, enterprises, and research institutions to accelerate the transformation of scientific research achievements and support the high-quality development of private enterprises in Zhengzhou [1][2] - Eleven private enterprises visited the Harbin Institute of Technology Zhengzhou Research Institute to learn about technological breakthroughs in fields such as medical health, optoelectronics, and intelligent manufacturing [1] - The North Beijing University Zhengzhou Research Institute showcased key projects in new materials and mixed reality digital technology, highlighting the industrialization potential of these research outcomes [1][2] Group 2 - The Shangjie District is actively exploring the integration of technological and industrial innovation, establishing a mechanism for continuous enterprise-research institution collaboration to facilitate project incubation and policy support [2] - The Harbin Institute of Technology Zhengzhou Research Institute and North Beijing University Zhengzhou Research Institute are deeply integrated into the innovation-driven development strategy of Henan Province, providing strong support for regional industrial transformation [2] - The Harbin Institute of Technology Zhengzhou Research Institute has successfully incubated companies like Henan Carbon True Core Material Technology, promoting advanced technologies in superhard materials and extending the industrial chain [2] Group 3 - The Zhengzhou Science and Technology Bureau plans to continue organizing diverse enterprise-research institution matching activities to support the establishment of joint innovation centers and accelerate the industrialization of scientific research achievements [3]
15.94亿!增长19.19%!美好医疗最新年报
思宇MedTech· 2025-04-18 09:52
分别在 2016 年、2018 年获得深圳市科创委技术攻关项目资助 市场与合作 报名:首届全球骨科大会 | 议程更新 报名:首届全球心血管大会 | 重磅亮点 合作伙伴征集:2025全球手术机器人大会 2025年4月18日, 美好医疗 发布了2024年年报。 # 财报数据 # 关于美好医疗 深圳市美好创亿医疗科技股份有限公司成立于 2010 年,总部位于深圳市龙岗区。公司主要产品包含一次性 使用无菌混合喷药装置、聚醚醚酮(PEEK)颅颌面固定板、一次性结扎夹等。还从事精密模具、自动化设 备、智能制造系统的设计、开发、生产及销售,以及医用植入金属材料、高分子材料、硅胶材料的制造等。 产品和技术 营业收入 : 2024 年实现营业收入 15.94 亿 元,同比增长 19.19% 。 其中,医疗业务收入 13.43 亿 元,占比 84.23%,同比增长 24.53%;非医疗业务收入 2.51 亿元,占比 15.77%,同比下降 3.04%, 医疗业务是推动公司整体营收上升的主要动力。 净利润 : 归属于上市公司股东的净利润为 3.64 亿 元,同比增长 16.11% ; 扣除非经常性损益后的净利 润为 3.5 亿元, ...